Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01305-25 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Hyoung Jin Kang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Triazoles, Antifungal Agents, Aspergillosis, Invasive Fungal Infections. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Children with invasive aspergillosis (IA) experience significant morbidity and mortality. Posaconazole is a broad-spectrum triazole antifungal agent indicated for IA treatment in adolescents and adults. A phase 2, open-label, noncomparative, multinational clinical trial in pediatric participants (2-to-
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Seoul National University College of Medicine, Seoul, Republic of Korea.
- Seoul National University Cancer Research Institute, Seoul, Republic of Korea.
- Seoul National University Children's Hospital, Seoul, Republic of Korea.
- Children's Hospital of Orange County, Orange, California, USA.
- University of California, Irvine, California, USA.
- Ghent University Hospital, Ghent, Belgium.
ORCID-Profile: Antonio C Arrieta, Matthew G Johnson
Zitieren
APA
Kang, H. J., Arrieta, A. C., Dhooge, C., Kelemen, Á., Macías-Parra, M., Aranda, L., Dinikina, Y. V., Kassis, I., Cesaro, S., Shepherd, A., Shah, A. K., Mackey, T., Waskin, H., & Johnson, M. G. (2026). Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01305-25
Vancouver
Kang HJ, Arrieta AC, Dhooge C, Kelemen Á, Macías-Parra M, Aranda L, et al. Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01305-25
BibTeX
@article{Kang2026,
author = {Kang, Hyoung Jin and Arrieta, Antonio C and Dhooge, Catharina and Kelemen, Ágnes and Macías-Parra, Mercedes and Aranda, Lourdes and Dinikina, Yulia V and Kassis, Imad and Cesaro, Simone and Shepherd, Aimee and Shah, Arvind K and Mackey, Tiffany and Waskin, Hetty and Johnson, Matthew G},
title = {Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01305-25}
}
EUVIMED